Avalo Therapeutics(US:AVTX) Globenewswire·2025-11-06 12:00Core Insights - Avalo Therapeutics is focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with a key emphasis on the Phase 2 LOTUS trial for AVTX-009 targeting hidradenitis suppurativa [1][11][12] Recent Corporate Highlights and Upcoming Anticipated Milestones - Enrollment in the Phase 2 LOTUS trial of AVTX-009 has been completed, with topline data expected in mid-2026 [6][7] - Kevin Lind has been appointed to the Board of Directors, bringing extensive experience in financial and corporate strategy [6][7] - The leadership team has been expanded with key appointments in business development and human resources [6][7] Third Quarter 2025 Financial Update - Cash and short-term investments totaled approximately $112 million as of September 30, 2025, expected to fund operations into 2028 [6][7] - Research and development expenses for Q3 2025 were $13.6 million, an increase of $4.1 million from Q3 2024, primarily due to costs associated with the LOTUS trial [7][10] - General and administrative expenses were $5.6 million for Q3 2025, up $1.3 million from Q3 2024, mainly driven by stock-based compensation [7][10] - The net loss for Q3 2025 was $30.6 million, compared to a net income of $23.0 million in Q3 2024, largely due to a $47.3 million change in other expenses [7][10] - Basic and diluted net loss per share for Q3 2025 was $2.19, compared to a basic net income per share of $0.98 for Q3 2024 [7][10] About AVTX-009 - AVTX-009 is a humanized monoclonal antibody that targets interleukin-1β (IL-1β), a key pro-inflammatory cytokine involved in various autoimmune disorders [12] - The LOTUS trial is designed to evaluate the efficacy and safety of AVTX-009 in approximately 250 adults with moderate to severe hidradenitis suppurativa [13]